Altimmune (ALT) EBIT Margin (2010 - 2025)

Altimmune (ALT) has 16 years of EBIT Margin data on file, last reported at 111126.92% in Q4 2025.

• On a quarterly basis, EBIT Margin rose 38619308.0% year-over-year to 111126.92% in Q4 2025; TTM through Dec 2025 was 230460.98%, a 28539902.0% increase from a year earlier, with the FY2025 full-year figure at 230460.98%, up 28539902.0% from the prior year.
• EBIT Margin for Q4 2025 stood at 111126.92%, up from 417180.0% in the prior quarter.
• Over the last five years, EBIT Margin for ALT reached as high as 731.92% in Q4 2021 and fell as low as 1237600.0% in Q3 2022.
• Historically, EBIT Margin has averaged 283564.09% across 5 years, with a median of 183032.21% in 2025.
• Across the five-year window, EBIT Margin tumbled 121658481 bps in 2022 and jumped 123137348 bps in 2023, its largest moves.
• Year by year, EBIT Margin stood at 731.92% in 2021, then tumbled by 12036 bps to 88823.08% in 2022, then declined by 2 bps to 90872.97% in 2023, then plunged by 447 bps to 497320.0% in 2024, then jumped by 78 bps to 111126.92% in 2025.
• Per Business Quant data, the three most recent EBIT Margin figures were 111126.92% in Q4 2025, 417180.0% in Q3 2025, and 458440.0% in Q2 2025.